Vuno Inc (338220) Fair Value & Analysis

Healthcare · KR · Market cap 103B KRW

Below-average quality, and screening another 80% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (2,112 KRW). The favourable scenario is already priced in.
• Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (1,115 KRW to 2,112 KRW) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 5,070 KRW – 65,500 KRW · fair‑value band 1,115 KRW – 2,112 KRW · the 8,480 KRW price screens above the 1,690 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Vuno Inc (338220) currently trades at 8,480 KRW, while our model-based Fair Value estimate is 1,690 KRW, implying the stock looks roughly 80.1% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Vuno Inc generated revenue of 33.4B KRW at a net margin of -19.4%. Revenue declined 19.7% year over year. It earns a return on equity of -18.9%. Net debt stands at 1.4B KRW. Fundamentals as of Jul 22, 2026

Our scenario range runs from 1,115 KRW (bear case) to 2,112 KRW (bull case); at 8,480 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 70% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -80%, 338220 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Vuno Inc. engages in the artificial intelligence medical software development and services business. The company provides medical AI solutions for analyzing various medical data and assisting in disease diagnosis.

Full company description

Vuno Inc. engages in the artificial intelligence medical software development and services business. The company provides medical AI solutions for analyzing various medical data and assisting in disease diagnosis. It also offers BoneAge, an AI diagnostic software for bone age assessment; DeepBrain, a brain parcellation for the quantitative analysis of neurodegenerative diseases and other neurological disorders; chest X-ray, a diagnostic support system for abnormalities in chest x-ray; fundus AI, an AI-based screening solution for various abnormalities in the fundus of the eye; DeepCARS, an AI-based cardiac arrest risk management system; and LungCT AI, an AI-based pulmonary lung nodule detection and reporting system. In addition, the company provides medical products under HATIV brand, such as HATIV K30, a kiosk-type medical device that measures electrocardiograms; HATIV P30, a medical ECG device; HATIV BP30, an automatic blood pressure monitoring device; and HATIV TP50T, an ear infrared thermometer device. The company was founded in 2014 and is headquartered in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Vuno Inc reported revenue of 34.8B KRW in FY2025 versus 2.2B KRW in FY2021, a compound +98.4%/yr. Reported net income was −5.8B KRW in FY2025.

338220 screens 80% overvalued. Compare with Veeva Systems Inc →

Peer Group

Health Information Services · 126 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.